Prosecution Insights
Last updated: April 19, 2026
Application No. 16/740,456

SYSTEMS AND METHODS FOR TREATING GLAUCOMA WITH PHOTODISRUPTIVE LASER PULSES

Final Rejection §112
Filed
Jan 12, 2020
Examiner
ROANE, AARON F
Art Unit
3792
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Eyex Solutions Inc.
OA Round
2 (Final)
73%
Grant Probability
Favorable
3-4
OA Rounds
3y 10m
To Grant
83%
With Interview

Examiner Intelligence

Grants 73% — above average
73%
Career Allow Rate
632 granted / 868 resolved
+2.8% vs TC avg
Moderate +10% lift
Without
With
+10.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 10m
Avg Prosecution
35 currently pending
Career history
903
Total Applications
across all art units

Statute-Specific Performance

§101
1.0%
-39.0% vs TC avg
§103
43.2%
+3.2% vs TC avg
§102
26.7%
-13.3% vs TC avg
§112
18.5%
-21.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 868 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without traverse of Species A4 (a combination of species A1, A2, and A3) in the reply filed on 09/03/2025 is acknowledged. Claims 25-26, and 31-32 have been withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected species, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 09/03/2025. Response to Arguments Applicant’s arguments with respect to claims 19-24, 27-30, and 33-38 have been considered but are moot because the new ground of rejection does not rely on any reference applied in the prior rejection of record for any teaching or matter specifically challenged in the argument. This action is made FINAL due to the amended (and/or new claims) and rejected claims. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 19-24, 27-30, and 36-38 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Both claims 19 and 27 recite subject matter not disclosed in the written description.. Claim 19 recites in lines 12-17 “initially photodisrupt tissue at an initial depth corresponding to the distal extent of the target volume of ocular tissue; and subsequently photodisrupt tissue at one or more subsequent depths between the distal extent of the target volume of ocular tissue and the proximal extent of the target volume of ocular tissue by moving a focus of the laser in a direction opposite the direction of propagation of the laser.” The written description does not support such a recitation. Claim 27 recites in lines 10-12 “initially photodisrupt ocular tissue at or near an interface between the Schlemm's canal and the trabecular meshwork; and subsequently photodisrupt ocular tissue of the trabecular meshwork.” The written description does not support such a recitation. Claim 37 recites in lines 7-11 “a control system in electrical communication with the optical laser subsystem for controlling the focus and scan of the laser beam to (1) initially photodisrupt tissue at an initial depth corresponding to a distal extent of the target volume and (2) to subsequently photodisrupt tissue at a subsequent depth that is proximal to the distal extent of the target volume by adjusting a focus of the laser.” The written description does not support such a recitation. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to AARON F ROANE whose telephone number is (571)272-4771. The examiner can normally be reached generally Mon-Fri 8am-9pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Niketa Patel can be reached at (571) 272-4156. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /AARON F ROANE/Primary Examiner, Art Unit 3792
Read full office action

Prosecution Timeline

Jan 12, 2020
Application Filed
Sep 30, 2021
Non-Final Rejection — §112
Jun 02, 2022
Response after Non-Final Action
Aug 29, 2022
Response Filed
Feb 07, 2024
Response after Non-Final Action
Feb 25, 2025
Response after Non-Final Action
Dec 09, 2025
Final Rejection — §112
Apr 13, 2026
Response after Non-Final Action

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599454
MECHANISMS AND METHODS TO CONTROL MOVEMENT OF A HEAD OF A MEDICAL SYSTEM RELATIVE TO AN ANATOMICAL SITE
2y 5m to grant Granted Apr 14, 2026
Patent 12599778
Precise Targeting of Beneficial Effects of Coherent Energy Using Nanoparticles
2y 5m to grant Granted Apr 14, 2026
Patent 12575852
TISSUE TREATMENT PROBE WITH BENT OPTICAL FIBER
2y 5m to grant Granted Mar 17, 2026
Patent 12564391
SURGICAL ROBOT SYSTEM
2y 5m to grant Granted Mar 03, 2026
Patent 12551304
CO-MANIPULATION SURGICAL SYSTEM FOR USE WITH SURGICAL INSTRUMENTS FOR PERFORMING SURGERY ACCORDING TO STORED SURGEON'S PREFERENCES
2y 5m to grant Granted Feb 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
73%
Grant Probability
83%
With Interview (+10.0%)
3y 10m
Median Time to Grant
Moderate
PTA Risk
Based on 868 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month